CRSP CRISPR Therapeutics AG - Common Shares
$56.87
价格 · 八月 19, 2026
截至...的财报数据 八月 3, 2026
52周区间
$44–$78
37% of range
分析师评级
HOLD
29 analysts
目标价
$88
+54% upside
P/E (TTM)
-8.8
ROE
-32.0%
净利润率
-16569.8%
关于 CRISPR Therapeutics AG - Common Shares 公司概况（来自维基百科）
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
阅读更多
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel (formerly CTX001), was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
History
CRISPR Therapeutics was founded in 2013 by Emmanuelle Charpentier, Shaun Foy and Rodger Novak. Charpentier later shared the Nobel Prize in Chemistry in 2020 with Jennifer Doudna. As part of a working group, she provided the first scientific documentation on the development and use of CRISPR gene editing. This allows DNA to be specifically modified and edited, which can be used to ameliorate diseases. CRISPR Therapeutics is applying this technology platform to research, develop and commercialize medicines for various diseases including sickle cell disease, beta thalassemia, various cancers, type 1 diabetes, and cardiovascular diseases. The CEO is Samarth Kulkarni, PhD, who joined the company in 2015 as chief business officer. Kulkarni became CEO in 2017.
CRISPR Therapeutics has formed collaborations in support of its mission of developing medicines. Vertex Pharmaceuticals and CRISPR Therapeutics entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. One of the first treatments to emerge from the joint research program was CTX001 or exagamglogene autotemcel (commonly known as Exa-cel). Subsequently, CRISPR Therapeutics and Vertex expanded their collaboration to include diseases like Duchenne muscular dystrophy and type 1 diabetes. In 2016, the company signed an agreement with Bayer AG to operate Casebia Therapeutics as a joint venture with Bayer under the management of CRISPR Therapeutics. The company went public on the NASDAQ exchange in October 2016.
CRISPR Therapeutics has established partnerships with additional companies such as Viacyte (part of Vertex), Nkarta, Capsida, Curevac, and others.
Products
CRISPR Therapeutics has drugs approved and in development for blood diseases, cancer, diabetes, and other severe diseases.
Exa-cel
Exa-cel is a drug therapy for the treatment of the rare blood disorders beta thalassemia and sickle cell disease developed jointly with Vertex Pharmaceuticals, that received FDA approval for clinical use in December 2023. In May 2020, exa-cel had received orphan drug designation from the US Food and Drug Administration (FDA) for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia. As of 2022 Phase 3 clinical trial results supported the safety and efficacy of this treatment. The rolling Biologics License Applications (BLAs) were submitted to the FDA for exa-cel for sickle cell disease and transfusion-dependent beta thalassemia. EU and UK filings were completed in 2022, and the submissions were validated by European Medicines Agency and The Medicines and Healthcare products Regulatory Agency as of April 2023.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
CRSP 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$56.87
市值
$5.45B
P/E (TTM)
-8.8
每股收益 (TTM)
$-6.47
营收 (TTM)
$4M
股息收益率
—
ROE
-32.0%
负债/权益
—
52周区间
$44 – $78
CRSP 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
$4M
2016-12-31
→
2025-12-31
EPS
$-6.47
2017-12-31
→
2025-12-31
自由现金流
$-346M
2016-12-31
→
2025-12-31
利润率
-16569.8%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
CRSP
同行中位数
P/E (TTM)
-8.8
—
P/S (TTM) (市销率 (TTM))
1553.7
56.3
P/B (市净率)
2.8
3.0
Price / FCF (股价/自由现金流)
-15.8
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
CRSP
同行中位数
Operating Margin (营业利润率)
-18933.7%
—
Net Profit Margin (净利润率)
-16569.8%
-1643.9%
ROA
-25.8%
-40.2%
ROE
-32.0%
-75.3%
ROIC
-34.8%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
CRSP
同行中位数
Current Ratio (流动比率)
13.3
6.7
Quick Ratio (速动比率)
13.2
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
CRSP
同行中位数
Revenue YoY (营收同比增长)
-90.6%
—
Revenue CAGR 3Y (营收3年复合年增长率)
43.1%
—
Revenue CAGR 5Y (营收5年复合年增长率)
37.3%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
CRSP
同行中位数
CRSP 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
29 位分析师
- 强烈买入 6 20.7%
- 买入 11 37.9%
- 持有 12 41.4%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
18 位分析师 · 2026-08-15
中位数
$80.00
现在
$56.87
最低
$44.00
最高
$291.00
中位数目标
$80.00
+40.7%
平均目标
$87.56
+54.0%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
0.01%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $-0.94 | $-1.22 | 0.28% |
| 2026年3月31日 | $-1.28 | $-1.25 | -0.03% |
| 2025年12月31日 | $-1.37 | $-1.18 | -0.19% |
| 2025年9月30日 | $-1.17 | $-1.29 | 0.12% |
| 2025年6月30日 | $-1.29 | $-1.45 | 0.16% |
| 2025年3月31日 | $-1.58 | $-1.28 | -0.30% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| CRSP | $5.03B | -8.1 | -90.6% | -16569.8% | -32.0% | — |
| MLTX | — | -3.7 | — | — | -60.5% | — |
| ACIU | — | — | — | — | — | — |
| ADCT | $444M | -3.2 | 14.8% | -175.3% | 74.1% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 15
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | $247.0K | |
| R&D Expense | $285M | $310M | $387M | $462M | $341M | $221M | $179M | $114M | $70M | $42M | $13M | |
| SG&A Expense | $74M | $73M | $76M | $102M | $100M | $86M | $63M | $48M | $36M | $31M | $13M | |
| Operating Expenses | $668M | $504M | $594M | $674M | $541M | $355M | $243M | $162M | $106M | $73M | $26M | |
| Operating Income | $-665M | $-467M | $-223M | $-673M | $374M | $-354M | $47M | $-159M | $-65M | $-68M | $-26M | |
| Interest Income | · | $104M | $76M | $23M | · | · | · | · | · | · | · | |
| Other Non-op | $87M | $104M | $72M | $23M | $6M | $6M | $26M | $-1M | $-197.0K | $79M | $16.0K | |
| Pretax Income | $-578M | $-363M | $-151M | $-650M | $380M | $-348M | $67M | $-164M | $-67M | $-23M | $-26M | |
| Income Tax | $4M | $4M | $3M | $-325.0K | $2M | $809.0K | $448.0K | $553.0K | $2M | $484.0K | $7.0K | |
| Net Income | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | $-26M | |
| EPS (Basic) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.97 | $-5.29 | $1.23 | $-3.44 | $-1.71 | · | · | |
| EPS (Diluted) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 | $-5.29 | $1.17 | $-3.44 | $-1.71 | · | · | |
| Shares (Basic) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 75,948,686 | 65,949,672 | 54,392,304 | 47,964,368 | 40,057,365 | · | · | |
| Shares (Diluted) | 89,925,109 | 84,359,126 | 79,220,930 | 77,746,575 | 80,393,496 | 65,949,672 | 56,932,798 | 47,964,368 | 40,057,365 | · | · | |
| EBITDA | $-645M | $-447M | $-203M | $-649M | $391M | $-345M | $51M | $-155M | $-62M | $-67M | · |
资产负债表 25
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $348M | $298M | $389M | $212M | $923M | $1.17B | $944M | $457M | $240M | $316M | $156M | |
| Short-term Investments | $1.63B | $1.61B | $1.30B | $1.60B | $1.46B | $522M | $0 | · | · | · | · | |
| Receivables | $0 | $25M | $200M | $0 | $305.0K | $144.0K | $99.0K | $88.0K | $3M | $3M | $339.0K | |
| Prepaid Expense | $10M | $8M | $14M | $38M | $38M | $26M | $44M | $10M | $6M | $2M | $540.0K | |
| Current Assets | $1.99B | $1.94B | $1.91B | $1.85B | $2.42B | $1.72B | $988M | $466M | $248M | $320M | $157M | |
| PP&E (Net) | $116M | $134M | $152M | $164M | $138M | $42M | $31M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $207M | $206M | $205M | $197M | $175M | $63M | $43M | $26M | $23M | $22M | $1M | |
| Accum. Depreciation | $91M | $72M | $53M | $34M | $38M | $21M | $12M | $7M | $4M | $942.0K | $72.0K | |
| Intangibles | · | $0 | $16.0K | $71.0K | $125.0K | $180.0K | $235.0K | $289.0K | $344.0K | $399.0K | $454.0K | |
| Other Non-current Assets | $24M | $16M | $2M | $5M | $5M | $1M | $1M | $669.0K | $606.0K | $198.0K | $101.0K | |
| Total Assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Accounts Payable | $11M | $15M | $38M | $27M | $15M | $9M | $6M | $5M | $2M | $5M | $2M | |
| Accrued Liabilities | $89M | $41M | $45M | $78M | $91M | $54M | $30M | $21M | $11M | $16M | $8M | |
| Current Liabilities | $149M | $88M | $109M | $121M | $120M | $94M | $57M | $28M | $15M | $22M | $10M | |
| Capital Leases | $188M | $206M | $223M | $228M | $213M | $50M | $44M | · | · | · | · | |
| Other Non-current Liabilities | $6M | $3M | $958.0K | $6M | $7M | $8M | $14M | $243.0K | $314.0K | $189.0K | $281.0K | |
| Total Liabilities | $343M | $310M | $347M | $368M | $352M | $164M | $127M | $97M | $84M | $112M | $124M | |
| Long-term Debt | $0 | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $181.0K | |
| Retained Earnings | $-1.95B | $-1.37B | $-1000M | $-846M | $-196M | $-574M | $-225M | $-292M | $-125M | $-57M | $-34M | |
| Treasury Stock | $60.0K | $62.0K | $62.0K | $63.0K | $63.0K | $63.0K | $63.0K | $57.0K | $0 | $0 | $0 | |
| AOCI | $5M | $2M | $2M | $-16M | $-5M | $-83.0K | $7.0K | $-8.0K | $14.0K | $-26.0K | $-8.0K | |
| Stockholders' Equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939M | $392M | $188M | $233M | $-29M | |
| Liabilities + Equity | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489M | $271M | $345M | $159M | |
| Shares Outstanding | 95,894,341 | 85,741,981 | 80,044,378 | 78,512,450 | 76,990,066 | 73,914,844 | 60,783,799 | 51,852,862 | 40,592,248 | 39,719,434 | 5,528,079 |
现金流 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $19M | $19M | $20M | $24M | $18M | $9M | $5M | $4M | $3M | $925.0K | $127.0K | |
| Stock-based Comp | $72M | $87M | $81M | $98M | $102M | $66M | $44M | $35M | $19M | $11M | $4M | |
| Deferred Tax | $915.0K | $-484.0K | $-424.0K | $-1M | $2M | $409.0K | $-34.0K | $6.0K | $180.0K | $-137.0K | $-54.0K | |
| Other Non-cash | $144M | $118M | $-207M | $33M | $39M | $35M | $-59M | $30M | $-24M | $-44M | · | |
| Operating Cash Flow | $-345M | $-143M | $-260M | $-496M | $539M | $-238M | $57M | $-96M | $-70M | $-53M | $59M | |
| CapEx | $914.0K | $2M | $9M | $37M | $82M | $18M | $7M | $3M | $8M | $3M | $1M | |
| Investing Cash Flow | $-32M | $-280M | $375M | $-259M | $-1.04B | $-541M | $1M | $-3M | $-8M | $32M | · | |
| Stock Issued | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | $0 | $89M | · | |
| Stock Repurchased | · | · | · | · | · | · | · | $57.0K | · | · | · | |
| Net Stock Activity | $398M | $301M | $33M | $970.0K | $213M | $982M | $415M | $307M | · | · | · | |
| Financing Cash Flow | $426M | $332M | $63M | $39M | $251M | $1.02B | $431M | $316M | $3M | $183M | · | |
| Net Change in Cash | $49M | $-91M | $177M | $-716M | $-246M | $237M | $489M | $217M | $-76M | $162M | $155M | |
| Taxes Paid | $3M | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $-346M | $-145M | $-270M | $-533M | $457M | $-257M | $50M | $-99M | $-78M | $-58M | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% | -49295.5% | 16.1% | -5087.8% | -157.7% | -1319.3% | · | |
| Net Margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% | -48520.9% | 23.1% | -5281.1% | -166.7% | -448.8% | · | |
| Pretax Margin | -16466.2% | -971.9% | -40.6% | -54298.8% | 41.5% | -48408.3% | 23.2% | -5263.4% | -162.5% | -439.9% | · | |
| EBITDA Margin | -18378.7% | -1198.8% | -54.6% | -54172.7% | 42.8% | -48018.2% | 17.8% | -4975.2% | -150.3% | -1301.4% | · | |
| ROA | -25.8% | -16.4% | -6.9% | -26.0% | 16.5% | -24.1% | 8.6% | -43.4% | -22.2% | -9.2% | · | |
| ROE | -32.0% | -18.9% | -8.5% | -34.0% | 15.4% | -23.2% | 8.7% | -40.8% | -32.5% | -22.8% | · | |
| ROIC | -34.8% | -24.4% | -12.0% | -35.9% | 15.5% | -21.3% | 4.9% | -40.7% | -35.3% | -29.9% | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 | 18.2 | 17.3 | 16.8 | 17.1 | 14.6 | · | |
| Quick Ratio | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 | 17.9 | 16.5 | 16.5 | 16.7 | 14.5 | · |
效率 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.2 | 0.0 | 0.4 | 0.0 | 0.4 | 0.0 | 0.1 | 0.0 | · | |
| Receivables Turnover | 0.3 | 0.3 | 3.7 | 7.9 | 4075.6 | 5.9 | 3097.2 | 2.3 | 14.2 | 3.0 | · |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -90.6% | -90.0% | 30885.5% | -99.9% | 127154.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 43.1% | -65.6% | 702.2% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 37.3% | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4M | $37M | $371M | $1M | $915M | $719.0K | $290M | $3M | $41M | $5M | · | |
| Net Income TTM | $-582M | $-366M | $-154M | $-650M | $378M | $-349M | $67M | $-165M | $-68M | $-23M | · | |
| Market Cap | $5.03B | $3.37B | $5.01B | $3.19B | $5.83B | $11.32B | $3.70B | $1.48B | $953M | $805M | · | |
| P/E | -8.1 | -9.1 | -32.3 | -4.9 | 16.1 | -28.9 | 52.1 | -8.3 | -13.7 | -2.9 | · | |
| P/S | 1432.7 | 90.4 | 13.5 | 2664.0 | 6.4 | 15740.1 | 12.8 | 474.2 | 23.2 | 155.8 | · | |
| P/B | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | 3.9 | 3.8 | 5.1 | 3.5 | · | |
| P / Tangible Book | 2.6 | 1.7 | 2.7 | 1.7 | 2.4 | 6.8 | · | · | · | · | · | |
| P / Cash Flow | -14.6 | -23.6 | -19.2 | -6.4 | 10.8 | -47.5 | 65.3 | -15.4 | -13.6 | -14.5 | · | |
| P / FCF | -14.5 | -23.3 | -18.6 | -6.0 | 12.8 | -44.1 | 74.1 | -15.0 | -12.2 | -13.8 | · | |
| Earnings Yield | -12.3% | -11.0% | -3.1% | -20.6% | 6.2% | -3.5% | 1.9% | -12.0% | -7.3% | -34.8% | · |
损益表 14
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $1M | $864.0K | $889.0K | $892.0K | $865.0K | $36M | $602.0K | $517.0K | $504.0K | $201M | $0 | $70M | $100M | $6.0K | $94.0K | |
| R&D Expense | $67M | $69M | $84M | $59M | $70M | $72M | $72M | $82M | $80M | $76M | $95M | $91M | $102M | $100M | $104M | $117M | |
| SG&A Expense | $18M | $17M | $18M | $17M | $19M | $19M | $18M | $17M | $19M | $18M | $16M | $18M | $19M | $22M | $21M | $27M | |
| Operating Expenses | $127M | $132M | $156M | $133M | $230M | $149M | $100M | $111M | $152M | $141M | $132M | $132M | $165M | $164M | $132M | $182M | |
| Operating Income | $-117M | $-130M | $-155M | $-132M | $-229M | $-148M | $-65M | $-110M | $-151M | $-141M | $70M | $-132M | $-95M | $-64M | $-132M | $-182M | |
| Other Non-op | $27M | $8M | $25M | $26M | $22M | $14M | $28M | $25M | $26M | $25M | $20M | $21M | $18M | $13M | $11M | $7M | |
| Pretax Income | $-90M | $-122M | $-130M | $-106M | $-207M | $-135M | $-37M | $-85M | $-125M | $-116M | $90M | $-112M | $-77M | $-52M | $-120M | $-175M | |
| Income Tax | $960.0K | $839.0K | $614.0K | $619.0K | $1M | $1M | $700.0K | $876.0K | $1M | $724.0K | $233.0K | $412.0K | $923.0K | $1M | $-9M | $-575.0K | |
| Net Income | $-91M | $-123M | $-131M | $-106M | $-209M | $-136M | $-37M | $-86M | $-126M | $-117M | $89M | $-112M | $-78M | $-53M | $-111M | $-175M | |
| EPS (Basic) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| EPS (Diluted) | $-0.94 | $-1.28 | $-1.32 | $-1.17 | $-2.40 | $-1.58 | $-0.41 | $-1.01 | $-1.49 | $-1.43 | $1.12 | $-1.41 | $-0.98 | $-0.67 | $-1.40 | $-2.24 | |
| Shares (Basic) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| Shares (Diluted) | 96,514,102 | 96,051,228 | -174,388,638 | 91,305,337 | 87,069,690 | 85,938,720 | -167,591,359 | 85,234,926 | 84,920,929 | 81,794,630 | -157,961,215 | 79,414,098 | 79,091,061 | 78,676,986 | -154,886,591 | 78,021,520 | |
| EBITDA | $-117M | $-126M | · | $-132M | $-229M | $-144M | · | $-110M | $-151M | $-136M | · | $-132M | $-95M | $-59M | · | $-182M |
资产负债表 25
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $291M | $423M | $348M | $286M | $194M | $235M | $298M | $226M | $484M | $707M | $389M | $528M | $445M | $344M | $212M | $494M | |
| Short-term Investments | $2.07B | $2.02B | $1.63B | $1.63B | $1.53B | $1.62B | $1.61B | $1.71B | $1.52B | $1.40B | · | $1.21B | $1.32B | $1.54B | · | $1.40B | |
| Receivables | · | · | $0 | $0 | $0 | $0 | $25M | $0 | $0 | $0 | · | · | $70M | · | · | $49.0K | |
| Prepaid Expense | $7M | $7M | $10M | $13M | $12M | $12M | $8M | $8M | $9M | $11M | · | $21M | $21M | $25M | · | $37M | |
| Current Assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | $1.87B | $1.94B | $1.94B | $2.01B | $2.12B | · | $1.76B | $1.86B | $1.91B | · | $1.93B | |
| PP&E (Net) | $108M | $112M | $116M | $121M | $125M | $129M | $134M | $139M | $143M | $147M | · | $156M | $159M | $162M | · | $166M | |
| PP&E (Gross) | $208M | $208M | $207M | $206M | $207M | $206M | $206M | $206M | $206M | $206M | · | $205M | $203M | $201M | · | $194M | |
| Accum. Depreciation | $100M | $95M | $91M | $86M | $82M | $77M | $72M | $68M | $63M | $58M | · | $49M | $44M | $39M | · | $28M | |
| Intangibles | · | · | · | · | · | · | · | $0 | $0 | $2.0K | · | $30.0K | $43.0K | $57.0K | · | $84.0K | |
| Other Non-current Assets | $38M | $29M | $24M | $24M | $25M | $21M | $16M | $16M | $15M | $9M | · | $2M | $2M | $3M | · | $4M | |
| Total Assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Accounts Payable | $11M | $14M | $11M | $12M | $10M | $13M | $15M | $16M | $9M | $16M | · | $26M | $28M | $45M | · | $32M | |
| Accrued Liabilities | $70M | $75M | $89M | $84M | $74M | $85M | $41M | $47M | $92M | $76M | · | $66M | $90M | $86M | · | $103M | |
| Current Liabilities | $133M | $136M | $149M | $119M | $104M | $119M | $88M | $90M | $128M | $119M | · | $111M | $133M | $147M | · | $151M | |
| Capital Leases | $179M | $184M | $188M | $193M | $197M | $202M | $206M | $211M | $215M | $219M | · | $227M | $230M | $225M | · | $231M | |
| Other Non-current Liabilities | $6M | $6M | $6M | $5M | $4M | $3M | $3M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $5M | |
| Total Liabilities | $904M | $911M | $343M | $329M | $319M | $337M | $310M | $316M | $359M | $355M | · | $359M | $381M | $389M | · | $399M | |
| Long-term Debt | $586M | $585M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $-2.16B | $-2.07B | $-1.95B | $-1.82B | $-1.71B | $-1.50B | $-1.37B | $-1.33B | $-1.24B | $-1.12B | · | $-1.09B | $-977M | $-899M | · | $-736M | |
| Treasury Stock | $60.0K | $60.0K | $60.0K | $60.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | $62.0K | · | $63.0K | $63.0K | $63.0K | · | $63.0K | |
| AOCI | $-5M | $-2M | $5M | $5M | $4M | $4M | $2M | $11M | $-3M | $-2M | · | $-7M | $-9M | $-9M | · | $-22M | |
| Stockholders' Equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | $1.83B | $1.93B | $1.94B | $1.98B | $2.08B | $1.88B | $1.73B | $1.82B | $1.85B | $1.88B | $1.95B | |
| Liabilities + Equity | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | $2.17B | $2.24B | $2.26B | $2.34B | $2.44B | · | $2.09B | $2.20B | $2.24B | · | $2.35B | |
| Shares Outstanding | 96,660,959 | 96,385,506 | 95,894,341 | 93,872,794 | 88,376,439 | 86,360,924 | 85,741,981 | 85,335,776 | 85,045,501 | 84,837,610 | · | 79,426,748 | 79,372,366 | 78,863,734 | · | 78,247,830 |
现金流 11
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $4M | $6M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $5M | |
| Stock-based Comp | $17M | $16M | $18M | $17M | $18M | $20M | $22M | $22M | $24M | $19M | $18M | $20M | $22M | $21M | $23M | $25M | |
| Other Non-cash | · | $-7M | · | · | · | $57M | · | · | · | $202M | · | · | · | $36M | · | · | |
| Operating Cash Flow | $-83M | $-109M | $-93M | $-85M | $-114M | $-54M | $-50M | $-107M | $-96M | $110M | $-96M | $-40M | $-133M | $9M | $-113M | $-105M | |
| CapEx | $648.0K | $504.0K | $517.0K | $74.0K | $117.0K | $206.0K | $254.0K | $219.0K | $707.0K | $721.0K | $738.0K | $2M | $4M | $3M | $6M | $6M | |
| Investing Cash Flow | $-56M | $-411M | $37M | $-119M | $70M | $-20M | $106M | $-162M | $-127M | $-98M | $-81M | $121M | $217M | $118M | $-176M | $87M | |
| Stock Issued | $0 | $-722.0K | $111M | $278M | $-22.0K | $9M | $15M | $6M | $-1M | $281M | $33M | $0 | $0 | $0 | $0 | $970.0K | |
| Net Stock Activity | · | $-722.0K | · | · | · | $9M | · | · | · | $281M | · | · | · | · | · | · | |
| Financing Cash Flow | $7M | $592M | $116M | $297M | $2M | $11M | $17M | $10M | $-466.0K | $306M | $39M | $2M | $17M | $5M | $2M | $15M | |
| Net Change in Cash | $-132M | $72M | $61M | $93M | $-42M | $-63M | $73M | $-259M | $-223M | $318M | $-139M | $83M | $100M | $132M | $-286M | $-3M | |
| Free Cash Flow | · | $-109M | · | · | · | $-54M | · | · | · | $109M | · | · | · | $6M | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1151.8% | -8933.3% | · | -14854.8% | -25709.0% | -17158.8% | · | -18294.0% | -29257.2% | -27894.2% | · | · | -136.0% | -64.5% | · | -194029.8% | |
| Net Margin | -895.3% | -8431.5% | · | -11973.1% | -23379.9% | -15722.1% | · | -14276.1% | -24450.3% | -23133.1% | · | · | -111.1% | -53.1% | · | -185690.4% | |
| Pretax Margin | -885.9% | -8373.9% | · | -11903.5% | -23235.1% | -15593.9% | · | -14130.6% | -24201.3% | -22989.5% | · | · | -109.7% | -51.7% | · | -186302.1% | |
| EBITDA Margin | -1151.8% | -8637.1% | · | -14854.8% | -25709.0% | -16611.3% | · | -18294.0% | -29257.2% | -26935.3% | · | · | -136.0% | -59.4% | · | -194029.8% | |
| ROA | -3.9% | -5.0% | · | -4.7% | -9.6% | -5.9% | · | -4.0% | -5.6% | -5.0% | · | -5.1% | -3.3% | -2.2% | · | -6.8% | |
| ROE | -5.3% | -6.8% | · | -5.5% | -11.3% | -7.0% | · | -4.7% | -6.7% | -5.9% | · | -6.1% | -4.0% | -2.6% | · | -7.8% | |
| ROIC | -6.8% | -7.2% | · | -6.9% | -13.5% | -8.2% | · | -5.7% | -7.7% | -6.8% | · | -7.7% | -5.3% | -3.6% | · | -9.3% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 17.8 | 18.0 | · | 16.2 | 16.6 | 15.6 | · | 21.6 | 15.7 | 17.8 | · | 15.8 | 14.0 | 13.0 | · | 12.8 | |
| Quick Ratio | 17.8 | 17.9 | · | 16.1 | 16.5 | 15.5 | · | 21.6 | 15.7 | 17.7 | · | 15.6 | 13.8 | 12.8 | · | 12.6 |
效率 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | · | · | · | · | · | · | · | 24.6 | 0.0 | 7.0 | · | · | 2.0 | · | · | 0.9 |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $13M | $4M | · | $3M | $3M | $2M | · | $2M | $71M | $171M | · | $170M | $170M | $101M | · | $2M | |
| Net Income TTM | $-529M | $-574M | · | $-537M | $-557M | $-465M | · | $-441M | $-433M | $-360M | · | $-418M | $-491M | $-593M | · | $-667M | |
| Market Cap | $5.27B | $4.59B | · | $6.08B | $4.30B | $2.94B | · | $4.01B | $4.59B | $5.78B | · | $3.61B | $4.46B | $3.57B | · | $5.11B | |
| P/E | -9.4 | -7.4 | · | -10.5 | -7.5 | -6.2 | · | -8.8 | -10.2 | -15.2 | · | -8.6 | -8.9 | -5.9 | · | -7.6 | |
| P/S | 392.8 | 1117.2 | · | 1873.1 | 1494.7 | 1181.2 | · | 2470.2 | 64.7 | 33.9 | · | 21.2 | 26.2 | 35.2 | · | 2536.5 | |
| P/B | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Tangible Book | 3.0 | 2.5 | · | 3.2 | 2.5 | 1.6 | · | 2.1 | 2.3 | 2.8 | · | 2.1 | 2.5 | 1.9 | · | 2.6 | |
| P / Cash Flow | · | -42.1 | · | · | · | -54.5 | · | · | · | 52.7 | · | · | · | 405.4 | · | · | |
| P / FCF | · | -41.9 | · | · | · | -54.3 | · | · | · | 53.0 | · | · | · | 621.4 | · | · | |
| Earnings Yield | -10.6% | -13.5% | · | -9.5% | -13.3% | -16.2% | · | -11.4% | -9.8% | -6.6% | · | -11.7% | -11.2% | -16.9% | · | -13.2% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $4M | $37M | $371M | $1M | $915M |
| 营业利润率 % | -18933.7% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| 净收入 | $-582M | $-366M | $-154M | $-650M | $378M |
| 稀释后每股收益 (EPS) | $-6.47 | $-4.34 | $-1.94 | $-8.36 | $4.70 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 13.3 | 22.1 | 17.5 | 15.3 | 20.2 |
| 速动比率 | 13.2 | 22.0 | 17.4 | 15.0 | 19.8 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-346M | $-145M | $-270M | $-533M | $457M |
最新新闻 提及该公司的近期头条新闻
- Small Caps Are Beating the S&P 500 by the Widest Margin Since 2003. These ETFs Let You Ride the Rally
- 2 Beaten-Down Stocks With Massive Upside Potential
- CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline
- CRISPR Therapeutics 股票极其便宜——分析师为何预计有 437% 的上涨潜力
- 巨型股增长领导地位还是小型股增长潜力？VUG 与 VBK
- 1 位华尔街顶尖分析师认为 CRISPR Therapeutics 的股价可能翻倍。您应该不计一切代价买入该股票吗？
- 检测到显著ETF资金外流 - ARKK, CRSP, TEM, HOOD
- 这家生物技术公司拥有可能重新定义其整个治疗领域的管线
- 凯西·伍德开始捡漏：她刚刚买入的两只股票
- 这是您的最佳机会，通过生物科技股票建立百万富翁地位吗？
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 574 家申报者 · $3.3B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 89 (0 与上一季度对比) | 47 (-13 与上一季度对比) | 148 (-24 与上一季度对比) | 145 (+21 与上一季度对比) | +5.4M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| ARK Investment Management LLC | $515999631 | 9460939 | 15.58% | 股份 |
| Orbis Allan Gray Ltd | $296334582 | 5433344 | 8.95% | 股份 |
| Capital World Investors | $259039094 | 4749525 | 7.82% | 股份 |
| STATE STREET CORP | $235703664 | 4321666 | 7.12% | 股份 |
| GSK plc | $175652997 | 3220627 | 5.30% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $117453717 | 2153015 | 3.55% | 股份 |
| SR One Capital Management, LP | $111194134 | 2038763 | 3.36% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $108459389 | 1988621 | 3.27% | 股份 |
| Sumitomo Mitsui Trust Group, Inc. | $93848832 | 1720734 | 2.83% | 股份 |
| Amova Asset Management Americas, Inc. | $93762487 | 1720097 | 2.83% | 股份 |
| EcoR1 Capital, LLC | $75771113 | 1389276 | 2.29% | 股份 |
| Capital International Investors | $69178918 | 1268407 | 2.09% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $64457935 | 1181847 | 1.95% | 股份 |
| NEA Management Company, LLC | $57734408 | 1058570 | 1.74% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $57694430 | 1057837 | 1.74% | 股份 |
| FMR LLC | $53577751 | 982357 | 1.62% | 股份 |
| D. E. Shaw & Co., Inc. | $48748506 | 893812 | 1.47% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $35380807 | 648713 | 1.07% | 股份 |
| UBS Group AG | $32419612 | 594419 | 0.98% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $31089982 | 570040 | 0.94% | 股份 |
| VANGUARD GROUP INC | $27714225 | 528494 | 0.84% | 股份 |
| CITADEL ADVISORS LLC | $25404514 | 465796 | 0.77% | 股份 |
| BANK OF AMERICA CORP /DE/ | $23509740 | 431055 | 0.71% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $23298288 | 427178 | 0.70% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $20836025 | 382032 | 0.63% | 股份 |
| IQ EQ FUND MANAGEMENT (IRELAND) Ltd | $20833789 | 381991 | 0.63% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $18456336 | 338400 | 0.56% | 卖出期权 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17763678 | 325700 | 0.54% | 买入期权 |
| Logos Global Management LP | $16362000 | 300000 | 0.49% | 股份 |
| CITADEL ADVISORS LLC | $15822054 | 290100 | 0.48% | 卖出期权 |
| Squarepoint Ops LLC | $15641472 | 286789 | 0.47% | 股份 |
| NORGES BANK | $14767032 | 270756 | 0.45% | 股份 |
| CITADEL ADVISORS LLC | $13973148 | 256200 | 0.42% | 买入期权 |
| GOLDMAN SACHS GROUP INC | $12748193 | 233740 | 0.38% | 股份 |
| JANE STREET GROUP, LLC | $12566016 | 230400 | 0.38% | 买入期权 |
| PEAK6 LLC | $11633382 | 213300 | 0.35% | 卖出期权 |
| Swiss National Bank | $9228168 | 169200 | 0.28% | 股份 |
| Susquehanna Portfolio Strategies, LLC | $8945978 | 164026 | 0.27% | 股份 |
| TWO SIGMA ADVISERS, LP | $8516256 | 162400 | 0.26% | 股份 |
| LPL Financial LLC | $8376280 | 153581 | 0.25% | 股份 |
| Bank of New York Mellon Corp | $8337366 | 152867 | 0.25% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $8301261 | 152205 | 0.25% | 股份 |
| Versant Venture Management, LLC | $8117243 | 148831 | 0.25% | 股份 |
| Pictet Asset Management Holding SA | $7989776 | 142213 | 0.24% | 股份 |
| Life Cycle Investment Partners Ltd | $7836962 | 143692 | 0.24% | 股份 |
| TD Asset Management Inc | $7777513 | 142602 | 0.23% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $7606257 | 139462 | 0.23% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $7230750 | 132577 | 0.22% | 股份 |
| RHUMBLINE ADVISERS | $6627197 | 121511 | 0.20% | 股份 |
| SFE Investment Counsel | $6229434 | 16700 | 0.19% | 卖出期权 |
| Private Advisor Group, LLC | $6060980 | 111129 | 0.18% | 股份 |
| EverSource Wealth Advisors, LLC | $6032669 | 110610 | 0.18% | 股份 |
| CONGRESS ASSET MANAGEMENT CO | $5969567 | 109453 | 0.18% | 股份 |
| BlackRock, Inc. | $5937061 | 108857 | 0.18% | 股份 |
| D. E. Shaw & Co., Inc. | $5901228 | 108200 | 0.18% | 买入期权 |
| Campbell & CO Investment Adviser LLC | $5864632 | 107529 | 0.18% | 股份 |
| JANE STREET GROUP, LLC | $5852142 | 107300 | 0.18% | 卖出期权 |
| California Public Employees Retirement System | $5599567 | 102669 | 0.17% | 股份 |
| CAPITAL INTERNATIONAL SARL | $5521521 | 101238 | 0.17% | 股份 |
| Affinity Asset Advisors, LLC | $5454000 | 100000 | 0.16% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $5439011 | 114337 | 0.16% | 股份 |
| CLOUGH CAPITAL PARTNERS L P | $5363300 | 98337 | 0.16% | 股份 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $5172465 | 94838 | 0.16% | 股份 |
| Slow Capital, Inc. | $5066439 | 92894 | 0.15% | 股份 |
| CAPITAL FUND MANAGEMENT S.A. | $4867258 | 89242 | 0.15% | 股份 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $4815606 | 101232 | 0.15% | 股份 |
| VANGUARD ASSET MANAGEMENT, Ltd | $4720437 | 86550 | 0.14% | 股份 |
| GROUP ONE TRADING LLC | $4638082 | 85040 | 0.14% | 股份 |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | $4575742 | 83897 | 0.14% | 股份 |
| STATE OF MICHIGAN RETIREMENT SYSTEM | $4502113 | 82547 | 0.14% | 股份 |
| Concurrent Investment Advisors, LLC | $4497728 | 82467 | 0.14% | 股份 |
| WELLS FARGO & COMPANY/MN | $4309151 | 79009 | 0.13% | 股份 |
| Fisher Asset Management, LLC | $4251957 | 77960 | 0.13% | 股份 |
| Trexquant Investment LP | $4225268 | 77471 | 0.13% | 股份 |
| COMMONWEALTH EQUITY SERVICES, LLC | $4194122 | 76900 | 0.13% | 股份 |
| JONES FINANCIAL COMPANIES LLLP | $4055652 | 73847 | 0.12% | 股份 |
| Man Group plc | $3992001 | 73194 | 0.12% | 股份 |
| PEAK6 LLC | $3834162 | 70300 | 0.12% | 买入期权 |
| ENVESTNET ASSET MANAGEMENT INC | $3822196 | 70081 | 0.12% | 股份 |
| ALGERT GLOBAL LLC | $3593095 | 65880 | 0.11% | 股份 |
| Walleye Trading LLC | $3528738 | 64700 | 0.11% | 卖出期权 |
| MILLENNIUM MANAGEMENT LLC | $3146958 | 57700 | 0.10% | 买入期权 |
| CAPITAL INTERNATIONAL LTD /CA/ | $3057840 | 56066 | 0.09% | 股份 |
| NOMURA HOLDINGS INC | $3055713 | 56027 | 0.09% | 股份 |
| Rafferty Asset Management, LLC | $3045132 | 55833 | 0.09% | 股份 |
| Green Alpha Advisors, LLC | $3043550 | 55804 | 0.09% | 股份 |
| Walleye Trading LLC | $3005154 | 55100 | 0.09% | 买入期权 |
| Caption Management, LLC | $2999700 | 55000 | 0.09% | 买入期权 |
| MetLife Investment Management, LLC | $2958413 | 54243 | 0.09% | 股份 |
| BENJAMIN EDWARDS INC | $2956845 | 54216 | 0.09% | 股份 |
| Quantinno Capital Management LP | $2869349 | 52610 | 0.09% | 股份 |
| Cetera Investment Advisers | $2856133 | 52368 | 0.09% | 股份 |
| STATE OF WISCONSIN INVESTMENT BOARD | $2788521 | 51128 | 0.08% | 股份 |
| CITIGROUP INC | $2781540 | 51000 | 0.08% | 买入期权 |
| CITIGROUP INC | $2781540 | 51000 | 0.08% | 卖出期权 |
| WOLVERINE ASSET MANAGEMENT LLC | $2727000 | 50000 | 0.08% | 卖出期权 |
| OSAIC HOLDINGS, INC. | $2693150 | 49381 | 0.08% | 股份 |
| Privium Fund Management B.V. | $2452882 | 44974 | 0.07% | 股份 |
| CANADA PENSION PLAN INVESTMENT BOARD | $2394306 | 43900 | 0.07% | 股份 |
| TUDOR INVESTMENT CORP ET AL | $2318604 | 42512 | 0.07% | 股份 |
公司内部人士 32 位内幕人士 · 12 位高管 · 16 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Samarth Kulkarni | Chief Executive Officer | 2026年3月20日 M | 255501 | 0 | 9 | $-10756932 |
| Brendan Smith | Chief Financial Officer | 2023年2月18日 M | 5072 | 0 | 0 | $0 |
| Michael John Tomsicek | Chief Financial Officer | 2021年3月11日 M | 1891 | 0 | 0 | $0 |
| Julianne Bruno | Chief Operating Officer | 2025年3月20日 M | 10544 | 0 | 0 | $0 |
| Lawrence Otto Klein | CBO & COO | 2022年8月16日 A | 26797 | 0 | 0 | $0 |
| Naimish Patel | Chief Medical Officer | 2026年5月29日 A | 19357 | 1 | 2 | $-312892 |
| James R. Kasinger | General Counsel and Secretary | 2026年5月29日 A | 94308 | 0 | 5 | $-645902 |
| Phuong Khanh Morrow | Chief Medical Officer | 2023年10月13日 A | 4411 | 0 | 0 | $0 |
| Tony W Ho | Executive VP, Head of R&D | 2021年12月3日 M | 52364 | 0 | 0 | $0 |
| Tyler Dylan-Hyde | Chief Legal Officer | 2018年1月16日 M | 25204 | 0 | 0 | $0 |
| Kala Subramanian | Senior Vice President, Strategic Development and Operations | 2017年6月15日 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Chief Scientific Officer | 2016年10月24日 C | 505617 | 0 | 0 | $0 |
| Christian Rommel | 董事 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Harold Edward Fleming | 董事 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Douglas A Treco | 董事 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Briggs Morrison | 董事 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Katherine A High | 董事 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Ali Behbahani | 董事 | 2026年6月5日 A | 14 | 0 | 0 | $0 |
| John Greene | 董事 | 2026年6月5日 A | 7000 | 0 | 0 | $0 |
| Simeon George | 董事 | 2026年6月5日 A | 1730179 | 0 | 0 | $0 |
| Maria Fardis | 董事 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Sandesh Mahatme | 董事 | 2026年6月5日 A | — | 0 | 0 | $0 |
| Bradley J Bolzon PhD | 董事 | 2022年6月9日 A | 148831 | 0 | 0 | $0 |
| Pablo J Cagnoni | 董事 | 2019年11月19日 M | 0 | 0 | 0 | $0 |
| Kurt Von Emster | 董事 | 2018年12月18日 S | 1171268 | 0 | 0 | $0 |
| Thomas Woiwode | 董事 | 2018年6月15日 A | 640014 | 0 | 0 | $0 |
| Anthony N Coles | 董事 | 2017年5月31日 A | 70000 | 0 | 0 | $0 |
| CELGENE CORP /DE/ | 10% 所有者 | 2017年12月4日 S | 3722534 | 0 | 0 | $0 |
| Hadley Harbor Master Investors (Cayman) L.P. | 10% 所有者 | 2016年10月24日 C | 744380 | 0 | 0 | $0 |
| GSK plc | 10% 所有者 | 2016年10月24日 C | 3220627 | 0 | 0 | $0 |
| Raju Prasad | — | 2026年8月7日 G | 14815 | 0 | 10 | $-5100841 |
| Rodger Novak | — | 2021年6月30日 S | 573007 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 6 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Versant Venture Capital IV, L.P., Versant Side Fund IV, L.P., Versant Ventures IV, LLC, Versant Venture Capital V, L.P., Versant Affiliates Fund V, L.P., Versant Ophthalmic Affiliates Fund I, L.P., Versant Ventures V, LLC, Versant Venture Capital V (Canada) LP, Versant Ventures V GP-GP (Canada), Inc., Versant Ventures V (Canada), L.P., Versant Venture Management, LLC ×5 申报 | 2021年2月16日 | — | 初始申报 | — | SEC |
| GlaxoSmithKline plc ×5 申报 | 2020年7月10日 | — | 初始申报 | — | SEC |
| Bayer Global Investments B.V., Bayer AG ×4 申报 | 2020年2月4日 | — | 初始申报 | — | SEC |
| Vertex Pharmaceuticals Incorporated (“Vertex US”), Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) ×4 申报 | 2019年6月7日 | — | 初始申报 | — | SEC |
| CELGENE ALPINE INVESTMENT CO. III, LLC, CELGENE CORPORATION ×4 申报 | 2018年2月8日 | — | 初始申报 | — | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP ×3 申报 | 2018年1月16日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 32 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| GNOM · Global X Funds | 3.85% | 38191 NS | 2026年5月31日 | N-PORT |
| IDNA · iShares Trust | 1.63% | 62247 SH | 2026年8月8日 | 每日 |
| LABU · Direxion Shares ETF Trust | 0.98% | 97235 NS | 2026年4月30日 | N-PORT |
| IBB · iShares Trust | 0.36% | 658537 SH | 2026年8月8日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.35% | 5248 SH | 2026年8月8日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.28% | 70696 SH | 2026年8月8日 | 每日 |
| IWN · iShares Trust | 0.27% | 752223 SH | 2026年8月8日 | 每日 |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.21% | 104016 NS | 2026年5月31日 | N-PORT |
| ISCV · iShares Trust | 0.15% | 20568 SH | 2026年8月8日 | 每日 |
| IWM · iShares Trust | 0.15% | 2353025 SH | 2026年8月8日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.15% | 536446 SH | 2026年8月8日 | 每日 |
| RSSL · Global X Funds | 0.15% | 39589 NS | 2026年4月30日 | N-PORT |
| PDN · Invesco Exchange-Traded Fund Trus... | 0.10% | 6636 SH | 2026年8月8日 | 每日 |
| ISCB · iShares Trust | 0.07% | 4136 SH | 2026年8月8日 | 每日 |
| SMLF · iShares Trust | 0.07% | 57970 SH | 2026年8月8日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.06% | 1106455 SH | 2026年8月8日 | 每日 |
| ESML · iShares Trust | 0.06% | 33283 SH | 2026年8月8日 | 每日 |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.06% | 108 NS | 2026年5月31日 | N-PORT |
| WSML · iShares Trust | 0.04% | 5486 SH | 2026年8月8日 | 每日 |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 13170 SH | 2026年8月8日 | 每日 |
| IWO · iShares Trust | 0.04% | 109974 SH | 2026年8月8日 | 每日 |
| OMFS · Invesco Exchange-Traded Self-Inde... | 0.03% | 1736 SH | 2026年8月8日 | 每日 |
| XT · iShares Trust | 0.03% | 21837 SH | 2026年8月8日 | 每日 |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0.03% | 3509 NS | 2026年5月31日 | N-PORT |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.01% | 7774 SH | 2026年8月8日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.01% | 20627 SH | 2026年8月8日 | 每日 |
| IYY · iShares Trust | 0.01% | 4231 SH | 2026年8月8日 | 每日 |
| ITOT · iShares Trust | 0.01% | 128511 SH | 2026年8月8日 | 每日 |
| AVUS · AMERICAN CENTURY ETF TRUST | 0.01% | 15609 NS | 2026年5月31日 | N-PORT |
| IWV · iShares Trust | 0.01% | 25457 SH | 2026年8月8日 | 每日 |
| AVSU · AMERICAN CENTURY ETF TRUST | 0.00% | 289 NS | 2026年5月31日 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.00% | 75392 SH | 2026年8月8日 | 每日 |